President Trump announced on Nov. 6 that the manufacturers of popular weight-loss drugs have agreed to reduce prices that Americans pay.

The announcement follows Trump’s executive order from May when he ordered pharmaceutical companies to address the higher price of their drugs in the U.S. compared to other countries, and to charge Americans the lowest price worldwide.

In the deal, Eli Lilly and Novo Nordisk agreed to drop prices of their injectable GLP-1-based drugs to $350 for a month’s supply, and to further reduce that cost to $245 over the next two years. The drugs currently cost about $1,000 for a month’s supply, or about half that amount if patients obtain them directly through the companies through newly launched direct-to-consumer programs. The pricing applies to a new version

See Full Page